Novartis Reports Rare Tumor Cases Following Zolgensma Treatment in Children
Swiss pharmaceutical company Novartis is facing increased regulatory scrutiny after disclosing nine reports of tumors in children who previously received its gene therapy Zolgensma, including two cases in which investigators found evidence connecting the tumors to the treatment. The disclosure, made public in November 2026, has prompted renewed attention to the long-term safety of one…
